halaven
(eribulin mesylate)BSP Pharmaceuticals SpA
6 results
halaven
(eribulin mesylate)Eisai Inc.Usage: HALAVEN is indicated for treating metastatic breast cancer in patients who have received at least two prior chemotherapy regimens, including anthracyclines and taxanes, and for unresectable or metastatic liposarcoma in patients previously treated with an anthracycline-containing regimen.ixempra
(ixabepilone)R-Pharm US Operating, LLCUsage: IXEMPRA is indicated for treating patients with metastatic or locally advanced breast cancer that is resistant to anthracyclines and taxanes, or when further anthracycline therapy is contraindicated. It can be used in combination with capecitabine or as a single agent when tumors are resistant to multiple treatments.jevtana
(cabazitaxel)Sanofi-Aventis U.S. LLCUsage: JEVTANA® is indicated for use with prednisone in treating patients with metastatic castration-resistant prostate cancer who have previously undergone treatment with a docetaxel-containing regimen.klisyri
(tirbanibulin)Almirall, LLCUsage: KLISYRI is indicated for the topical treatment of actinic keratosis specifically on the face or scalp.paclitaxel
(Paclitaxel)Teva Pharmaceuticals, Inc.Usage: Paclitaxel Protein-Bound Particles for Injectable Suspension is indicated for treating metastatic breast cancer post-chemotherapy failure, first-line therapy for non-small cell lung cancer in combination with carboplatin, and first-line treatment of metastatic adenocarcinoma of the pancreas with gemcitabine.